[PDF] Top 20 Pathways in pulmonary arterial hypertension: the future is here

... Idiopathic Pulmonary Fibrosis Clinical (MUSIC) study (a phase II trial of macitentan in idiopathic pulmonary fibrosis), the incidence of liver enzyme elevations with macitentan was similar to placebo ... See full document

... Pulmonary arterial hypertension (PAH) has evolved from a disease with limited treatment options to one where numerous therapies that target three key pathophysiological pathways in the disease ... See full document

... major pathways inv- olved in development and progression of PAH: 1) the endothelin pathway targeted by the endothelin receptor antagonists (ERAs); 2) the prostacyclin pathway, targeted by prostacyclin analogues; ... See full document

... the pathways involved and their interactions, we will hopefully increase the efficacy of novel therapeutic strategies for this severe disease and further improve the palliative therapy for PAH and ultimately cure  ... See full document

... survival pathways (Figure 2 and ...experimental pulmonary hypertension by inducing apoptosis of SMCs ...experimental pulmonary hypertension was also achieved by blocking a downstream ... See full document

... PDGFR-b, its ligand and its phosphorylated state and EGFR were observed in plexiform lesions of IPAH patients. Their active participation in plexiform lesion formation remains speculative, but Perros et al. [33] ... See full document

... different pathways, among others not discussed in the present summary, is incredibly promising for the future of pulmonary arterial ...in pulmonary arterial hyper- tension ... See full document

... A total of 178 subjects were enrolled, with 119 randomized to receive macitentan. After 12 months of treatment with 10 mg of macitentan, the treatment group demonstrated no significant difference in forced vital ... See full document

... by pathways associated with pulmonary arterial hypertension (PAH), and is present at elevated levels within pulmonary vascular lesions and sera from patients with idiopathic PAH ...in ... See full document

... targeted by endothelin receptor antagonists such as bosentan, sitaxsentan and ambrisentan; 2) the nitric oxide pathway, acted upon by phosphodiesterase type 5 inhibitors such as sildenafil; and 3) the prostacyclin ... See full document

... 'Pulmonary hypertension due to left heart diseases' is divided into three sub-groups: systolic dysfonction, diastolic dysfonction and valvular ...'Pulmonary hypertension due to respiratory ... See full document

... In general, survival rates of patients with PAH have improved coincidentally with the introduction of a range of specific therapies, but prognosis still remains poor [20], indicating that new approaches are still needed. ... See full document

... which pulmonary arterial hyperten- sion (PAH) (group 1 of the PH classi fi cation) coexists with COPD by chance (Figure ...“ pulmonary vascular phenotype ” to de fi ne this subgroup of ...The ... See full document

... from pulmonary hypertension (PH) under optimal medical care in an effort to better fill the existing gap on the knowledge about the broader distribution of PAH in the ... See full document

... small pulmonary arteries [15–17], and therefore from the resistance ...the arterial load and, therefore, compliance (or stiffness; the reciprocal of compliance) is an important factor contributing to ... See full document

... PAH may manifest during pregnancy and some women are diagnosed with PAH during this time. Current data and our experience suggest that there is a higher risk of complications associated with this group of women, ... See full document

... inhibition of MRP4 in PASMCs modified the intracellular content of cyclic nucleotides and resulted in an activation of the down- stream pathways, namely PKA and PKG (29, 30), as shown by VASP phosphorylation. ... See full document

... Recent investigations have suggested that it might be possible to reverse the pathology of pul- monary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal despite current ... See full document

... decrease in pulmonary vascular resistance and pulmonary artery pressure. A comparison of three inhaled treprostinil regimens, ie, 7.5 µ g over six minutes, 15 µ g over six minutes, or 15 µ g over three ... See full document

... Regardless as to the amount of time that had past, participants’ pictorial representations of their PAH journey were largely focused on the pre-diagnostic period which included the use of stimulus materials that ... See full document